Please assess the completion status of the following clinical trial:

Trial Title: S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytologic diagnosis of esophageal carcinoma~* ECOG performance status 0-1~* Age:70-85 years~* Joined the study voluntarily and signed informed consent form~* Patients must not have received any prior anticancer therapy~* Stage Ⅰ-ⅣB（AJCC 2009）~* Target lesions can be measured according to RECIST criteria~* No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin ≥9 g/dL, WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L, platelet count ≥100x 109/L, TBIL\<1.5 x ULN, ALT and AST ≦ 2.5 x ULN, creatinine ≦ 1.5 x ULN~Exclusion Criteria:~* Multiple carcinomas of the esophagus,~* Biopsy-proven invasion of the tracheobronchial tree or tracheoesophageal fistula,~* Metastatic disease (M1b),~* A primary tumor that extended to within 2 cm of the gastroesophageal junction,~* Prior chemotherapy, prior thoracic radiation, surgical resection of the primary tumor,~* history of a second malignancy other than nonmelanoma skin cancer

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- chemoradiotherapy (Type: EXPERIMENTAL): Radiotherapy 54 Gy was administered in 1.8 Gy fractions 5 times weekly. S-1 70mg/m2 was administered on days 1-14 and 29-42
- Radiotherapy 60 Gy (Type: ACTIVE_COMPARATOR): Radiotherapy 60 Gy was administered in 2Gy fractions 5 times weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).